Please login to the form below

Not currently logged in

Xarelto effective in reducing blood clots

A study shows that following total knee replacement surgery, Xarelto reduces the relative risk of blood clots when compared with enoxaparin

A study published in The Lancet shows that following total knee replacement surgery, Xarelto (rixaroxoban) reduces the relative risk of blood clots by more than 30 per cent when compared with enoxaparin.

The results come from the Phase III RECORD4 trial comparing Bayer's anticoagulant Xarelto, administered as a once-daily tablet with enoxaprin, a twice-daily injection.

Professor Beverley Hunt, consultant haematologist and medical director of Lifeblood said: "We want to ensure that every adult admitted to hospital in the UK receives appropriate prevention against hospital-acquired clots, which are the number one cause of preventable deaths in hospital care. We welcome rivaroxaban which has the advantages of being a tablet and has proven to be superior to the gold standard in clinical trials after knee replacements"

As Xarelto is in tablet form it does not need to be administered by a healthcare practitioner, unlike the injectable, twice-daily enoxaparin.

"Blood clots after major orthopaedic surgery remain a serious clinical problem," said Professor Ajay Kakkar, professor of surgical sciences at the Barts and the London School of Medicine and Dentistry, and director of the Thrombosis Research Institute. "Rivaroxaban will add to our armamentarium of thrombosis-preventing strategies and help in their use after hospital discharge," he continued.

Xarelto is approved in the EU, among other countries, for the prevention of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery.

6th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...